PMC:7228307 / 2437-2655
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T13 | 10-18 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T17 | 34-46 | Sentence | denotes | Introduction |
| T18 | 47-182 | Sentence | denotes | The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T13 | 10-18 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T17 | 34-46 | Sentence | denotes | Introduction |
| T18 | 47-182 | Sentence | denotes | The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy. |